Jessica C. Seeliger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jessica C. Seeliger has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Mary L. Previti
Stony Brook University
12 shared publicationsNeetika Jaisinghani
Stony Brook University
6 shared publicationsLia A. Parkin
Department of Microbiology and Immunology, Stony Brook University, Stony Brook, NY, United States
5 shared publicationsLu Bai
Department of Chemistry, Stony Brook University, 100 Nicolls Road, Stony Brook, NY 11794
5 shared publicationsBeatrix Ueberheide
Proteomics Laboratory, New York University Grossman School of Medicine, New York, NY 10016, USA; Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY 10016, USA
4 shared publicationsErik R. Van Vlack
Department of Pharmacological Sciences, Stony Brook University, Stony Brook, New York 11794, United States
4 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Annual Reviews in Annual Review of Microbiology
- Vol. 80 (1) , 331-353
Adapting Architecture: Lipid Membrane Remodeling in Mycobacteria
The mycobacterial cell envelope is a formidable barrier, regarded as one of the most chemically and structurally elaborate architectures in the Bacteria kingdom. Membrane remodeling, defined as changes in membrane lipid composition in response to stressors, has been a subject of broad investigation because of its implications for permeability, antibiotic susceptibility, immunogenicity, and virulence. However, because remodeling is a highly dynamic process governed by multiple, deeply interconnected cellular response pathways, its underlying mechanisms and biophysical consequences remain incompletely understood. In this review, we synthesize the current knowledge of how the composition and organization of membrane lipids shift under physiologically relevant conditions, and we examine how these changes intersect with key stress response pathways. As a unifying thread connecting lipid composition, envelope architecture, and cellular function, we summarize our understanding of mycobacterial membrane biophysical properties, highlighting recent advances as well as conceptual and methodological gaps that remain in the field.
- 23 October 2026
- Published by Annual Reviews in Annual Review of Microbiology
- Vol. 80 (1) , 331-353
Open AccessAdapting Architecture: Lipid Membrane Remodeling in Mycobacteria
The mycobacterial cell envelope is a formidable barrier, regarded as one of the most chemically and structurally elaborate architectures in the Bacteria kingdom. Membrane remodeling, defined as changes in membrane lipid composition in response to stressors, has been a subject of broad investigation because of its implications for permeability, antibiotic susceptibility, immunogenicity, and virulence. However, because remodeling is a highly dynamic process governed by multiple, deeply interconnected cellular response pathways, its underlying mechanisms and biophysical consequences remain incompletely understood. In this review, we synthesize the current knowledge of how the composition and organization of membrane lipids shift under physiologically relevant conditions, and we examine how these changes intersect with key stress response pathways. As a unifying thread connecting lipid composition, envelope architecture, and cellular function, we summarize our understanding of mycobacterial membrane biophysical properties, highlighting recent advances as well as conceptual and methodological gaps that remain in the field.
- Open Access
- 14 October 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (11) , 3643-3654
Cytoplasmic C-Terminal Domain of the MmpL11 Lipid Transporter Is Required for Interaction with Its Co-cistronic Partner MSMEG_0240 in Mycobacterium smegmatis
MmpL proteins play an important role in the various mechanisms associated with mycobacterial virulence. Identification of interacting protein partners by classical in vitro methods is hampered by the low solubility of these integral membrane proteins. In this study, we used two independent biotin proximity labelling assays (APEX2 and BioID) to define the proxisome of MmpL11 in Mycobacterium smegmatis. Crucially, these techniques are performed directly in the organism of interest, allowing the detection of potentially transient or weak interactions in multiprotein complexes and preserving the subcellular structures and the presence of cofactors or post-translational modifications that can also impact protein–protein interactions. BioID leads to the biotinylation of lysine residues, whereas APEX2 leads to the biotinylation of mainly tyrosine residues; they have also been shown to have different effective labelling radii. On one hand, an interaction was detected between the cytoplasmic C-terminal domain of MmpL11 and MSMEG_0240, a protein of unknown function, using BioID. This interaction was confirmed using both MmpL11 and MSMEG_0240 as fusions with BirA and was further supported by AlphaFold3 prediction. On the other hand, APEX2 did not detect proximity between MmpL11 and MSMEG_0240, probably due to the absence of accessible tyrosines. However, both approaches identified MSMEG_0940 as an additional interactant with MmpL11 that also depends on its C-terminal domain. Overall, this study demonstrates the utility of APEX2 and BioID as complementary tools for defining the proxisome of mycobacterial proteins.
- 14 October 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (11) , 3643-3654
Open AccessCytoplasmic C-Terminal Domain of the MmpL11 Lipid Transporter Is Required for Interaction with Its Co-cistronic Partner MSMEG_0240 in Mycobacterium smegmatis
MmpL proteins play an important role in the various mechanisms associated with mycobacterial virulence. Identification of interacting protein partners by classical in vitro methods is hampered by the low solubility of these integral membrane proteins. In this study, we used two independent biotin proximity labelling assays (APEX2 and BioID) to define the proxisome of MmpL11 in Mycobacterium smegmatis. Crucially, these techniques are performed directly in the organism of interest, allowing the detection of potentially transient or weak interactions in multiprotein complexes and preserving the subcellular structures and the presence of cofactors or post-translational modifications that can also impact protein–protein interactions. BioID leads to the biotinylation of lysine residues, whereas APEX2 leads to the biotinylation of mainly tyrosine residues; they have also been shown to have different effective labelling radii. On one hand, an interaction was detected between the cytoplasmic C-terminal domain of MmpL11 and MSMEG_0240, a protein of unknown function, using BioID. This interaction was confirmed using both MmpL11 and MSMEG_0240 as fusions with BirA and was further supported by AlphaFold3 prediction. On the other hand, APEX2 did not detect proximity between MmpL11 and MSMEG_0240, probably due to the absence of accessible tyrosines. However, both approaches identified MSMEG_0940 as an additional interactant with MmpL11 that also depends on its C-terminal domain. Overall, this study demonstrates the utility of APEX2 and BioID as complementary tools for defining the proxisome of mycobacterial proteins.
- Open Access
Loss of riboflavin biosynthesis leads to accumulation of select aromatic amino acids and loss of infectivity in Mycobacterium tuberculosis
Riboflavin biosynthesis is required for in vitro survival of the human pathogen Mycobacterium tuberculosis ( Mtb ). However, despite the lack of a known transporter, growth can be rescued by exogenous riboflavin. The riboflavin biosynthesis pathway is also predicted essential in vivo , but whether riboflavin levels available in the host can support survival has not been directly tested. Here we constructed a set of inducible CRISPR interference (CRISPRi) knockdown and targeted gene deletion strains for known riboflavin biosynthesis genes ( ribA2, ribG, ribH, ribC ) as tools to characterize riboflavin requirements, uptake, and metabolite changes and to assess in vivo essentiality. We found that riboflavin, but not flavin adenine dinucleotide or flavin mononucleotide, rescued auxotrophy for all strains tested. Further, riboflavin uptake was not affected by disruption of proton motive force or ATP synthesis, suggesting that uptake is not via an active mechanism. Targeted metabolite profiling after removal of riboflavin from growth medium confirmed reduced riboflavin levels. While other riboflavin intermediates were not detected, significant accumulation of aromatic amino acids (Phe, Tyr) was observed across all assayed strains, as well as alteration in a vitamin B9 metabolite. Selecting the ribC knockout as a representative strain, we found that riboflavin depletion had a bacteriostatic effect as late as 3 weeks after removal. Unexpectedly, Δ ribC lacked infectivity in an aerosol mouse infection, suggesting that the potential to scavenge riboflavin from the host is not sufficient to survive in vivo . Overall, our results show that altered metabolism upon loss of riboflavin biosynthesis leads to compromised Mtb infectivity. IMPORTANCE: Tuberculosis remains one of the world’s most deadly infectious diseases, underscoring the need to explore new drug targets. Riboflavin (vitamin B2) biosynthesis has emerged as a promising target because Mycobacterium tuberculosis ( Mtb ) depends on this pathway for survival. The riboflavin pathway also produces metabolites that modulate host mucosal-associated invariant T (MAIT) cell activity, towards understanding potential strategies for host-directed therapies. Here we found that disrupting riboflavin biosynthesis led to not only compromised survival, but also widespread changes to metabolism and loss of the ability to establish infection in an animal model. These findings improve our understanding of how Mtb adapts to metabolic stress, with implications for developing drugs that target riboflavin biosynthesis and for alterations in host immunity to be explored in future studies.
Open AccessLoss of riboflavin biosynthesis leads to accumulation of select aromatic amino acids and loss of infectivity in Mycobacterium tuberculosis
Riboflavin biosynthesis is required for in vitro survival of the human pathogen Mycobacterium tuberculosis ( Mtb ). However, despite the lack of a known transporter, growth can be rescued by exogenous riboflavin. The riboflavin biosynthesis pathway is also predicted essential in vivo , but whether riboflavin levels available in the host can support survival has not been directly tested. Here we constructed a set of inducible CRISPR interference (CRISPRi) knockdown and targeted gene deletion strains for known riboflavin biosynthesis genes ( ribA2, ribG, ribH, ribC ) as tools to characterize riboflavin requirements, uptake, and metabolite changes and to assess in vivo essentiality. We found that riboflavin, but not flavin adenine dinucleotide or flavin mononucleotide, rescued auxotrophy for all strains tested. Further, riboflavin uptake was not affected by disruption of proton motive force or ATP synthesis, suggesting that uptake is not via an active mechanism. Targeted metabolite profiling after removal of riboflavin from growth medium confirmed reduced riboflavin levels. While other riboflavin intermediates were not detected, significant accumulation of aromatic amino acids (Phe, Tyr) was observed across all assayed strains, as well as alteration in a vitamin B9 metabolite. Selecting the ribC knockout as a representative strain, we found that riboflavin depletion had a bacteriostatic effect as late as 3 weeks after removal. Unexpectedly, Δ ribC lacked infectivity in an aerosol mouse infection, suggesting that the potential to scavenge riboflavin from the host is not sufficient to survive in vivo . Overall, our results show that altered metabolism upon loss of riboflavin biosynthesis leads to compromised Mtb infectivity. IMPORTANCE: Tuberculosis remains one of the world’s most deadly infectious diseases, underscoring the need to explore new drug targets. Riboflavin (vitamin B2) biosynthesis has emerged as a promising target because Mycobacterium tuberculosis ( Mtb ) depends on this pathway for survival. The riboflavin pathway also produces metabolites that modulate host mucosal-associated invariant T (MAIT) cell activity, towards understanding potential strategies for host-directed therapies. Here we found that disrupting riboflavin biosynthesis led to not only compromised survival, but also widespread changes to metabolism and loss of the ability to establish infection in an animal model. These findings improve our understanding of how Mtb adapts to metabolic stress, with implications for developing drugs that target riboflavin biosynthesis and for alterations in host immunity to be explored in future studies.
- 11 February 2026
- Published by Elsevier
- Vol. 727, 161-177
Tagging lipoproteins in mycobacteria via metabolic incorporation of modified fatty acids
- 11 February 2026
- Published by Elsevier
- Vol. 727, 161-177
Tagging lipoproteins in mycobacteria via metabolic incorporation of modified fatty acids
- Open Access
The cytoplasmic C-terminal domain of the MmpL11 lipid transporter is required for interaction with its co-cistronic partner MSMEG_0240 in Mycobacterium smegmatis
MmpL proteins play an important role in the various mechanisms associated with mycobacterial virulence. Identification of interacting protein partners required for a detailed understanding of their role remains hampered because of their large size (> 100 kDa) and the presence of twelve transmembrane domains by classical methods. In this study, we used two independent biotin proximity labelling assays (APEX2 and BioID) to define the proxisome of MmpL11 in M. smegmatis . Indeed, these techniques are performed directly in the organism of interest, allowing the detection of potentially transient or weak interactions in multiprotein complexes and preserving the subcellular structures and the presence of cofactors or post-translational modifications that can also impact protein-protein interactions. BioID leads to the biotinylation of lysine residues, whereas APEX2 leads to the biotinylation of mainly tyrosine residues; they have also been shown to have different effective labelling radii. On one hand, an interaction was detected between the cytoplasmic C-terminal domain of MmpL11 and MSMEG_0240, a protein of unknown function, using BioID. This interaction was confirmed using both MmpL11 and MSMEG_0240 as fusions with BirA and was corroborated by AlphaFold3 prediction. On the other hand, APEX2 failed to detect an interaction between MmpL11 and MSMEG_0240, probably due to the absence of accessible tyrosines. However, both approaches identified MSMEG_0940 as an additional interactant with MmpL11 that also depends on the C-terminal domain. Overall, this study demonstrates that APEX2 and BioID as complementary tools for defining the proxisome of mycobacterial proteins.
Open AccessThe cytoplasmic C-terminal domain of the MmpL11 lipid transporter is required for interaction with its co-cistronic partner MSMEG_0240 in Mycobacterium smegmatis
MmpL proteins play an important role in the various mechanisms associated with mycobacterial virulence. Identification of interacting protein partners required for a detailed understanding of their role remains hampered because of their large size (> 100 kDa) and the presence of twelve transmembrane domains by classical methods. In this study, we used two independent biotin proximity labelling assays (APEX2 and BioID) to define the proxisome of MmpL11 in M. smegmatis . Indeed, these techniques are performed directly in the organism of interest, allowing the detection of potentially transient or weak interactions in multiprotein complexes and preserving the subcellular structures and the presence of cofactors or post-translational modifications that can also impact protein-protein interactions. BioID leads to the biotinylation of lysine residues, whereas APEX2 leads to the biotinylation of mainly tyrosine residues; they have also been shown to have different effective labelling radii. On one hand, an interaction was detected between the cytoplasmic C-terminal domain of MmpL11 and MSMEG_0240, a protein of unknown function, using BioID. This interaction was confirmed using both MmpL11 and MSMEG_0240 as fusions with BirA and was corroborated by AlphaFold3 prediction. On the other hand, APEX2 failed to detect an interaction between MmpL11 and MSMEG_0240, probably due to the absence of accessible tyrosines. However, both approaches identified MSMEG_0940 as an additional interactant with MmpL11 that also depends on the C-terminal domain. Overall, this study demonstrates that APEX2 and BioID as complementary tools for defining the proxisome of mycobacterial proteins.
- 7 January 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (2) , 637-652
Measuring Membrane Fluidity in Live Mycobacteria Reveals Subcellular Lateral Variation And Pole-Selective Responses to Mycomembrane Perturbation
The cell envelope is an oft-cited factor in the ability of mycobacteria to tolerate antibiotics, host immunity, and environmental stress. In vitro studies have led to a prevailing model in which the mycobacterial envelope exhibits low fluidity that hinders the entry of antibiotics and other stressors. While membrane fluidity affects essential processes and is dynamically regulated across all domains of life, few studies have measured membrane fluidity in live mycobacteria. To address this gap, we used the environmentally sensitive probe C-Laurdan to develop an imaging- and flow cytometry-based method for measuring cell envelope fluidity directly in live cells. Our approach enables cell envelope labeling across diverse mycobacterial species, including M. smegmatis and M. tuberculosis. We characterized fluidity as a function of subcellular localization, antibiotic treatment, and genetic perturbation. The unusual growth characteristics of mycobacteria, including polar growth and asymmetric growth and division, contribute to intercellular heterogeneity that is thought to enhance survival under stress. Indeed, we observed that the poles are more fluid than sidewalls, and that the old pole is more fluid than the new pole. Further, daughter cells have unequal membrane fluidity upon division and this asymmetry is reduced in a mutant with decreased asymmetric polar growth. Chemical or genetic disruption of the mycomembrane led to a shared alteration of the fluidity pattern and susceptibility to two antibiotics, suggesting that membrane fluidity signatures may predict antibiotic susceptibility. This approach expands the toolkit for assessing fluidity in mycobacteria and enables deeper investigation into how biophysical properties influence bacterial physiology and antibiotic susceptibility.
- 7 January 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (2) , 637-652
Measuring Membrane Fluidity in Live Mycobacteria Reveals Subcellular Lateral Variation And Pole-Selective Responses to Mycomembrane Perturbation
The cell envelope is an oft-cited factor in the ability of mycobacteria to tolerate antibiotics, host immunity, and environmental stress. In vitro studies have led to a prevailing model in which the mycobacterial envelope exhibits low fluidity that hinders the entry of antibiotics and other stressors. While membrane fluidity affects essential processes and is dynamically regulated across all domains of life, few studies have measured membrane fluidity in live mycobacteria. To address this gap, we used the environmentally sensitive probe C-Laurdan to develop an imaging- and flow cytometry-based method for measuring cell envelope fluidity directly in live cells. Our approach enables cell envelope labeling across diverse mycobacterial species, including M. smegmatis and M. tuberculosis. We characterized fluidity as a function of subcellular localization, antibiotic treatment, and genetic perturbation. The unusual growth characteristics of mycobacteria, including polar growth and asymmetric growth and division, contribute to intercellular heterogeneity that is thought to enhance survival under stress. Indeed, we observed that the poles are more fluid than sidewalls, and that the old pole is more fluid than the new pole. Further, daughter cells have unequal membrane fluidity upon division and this asymmetry is reduced in a mutant with decreased asymmetric polar growth. Chemical or genetic disruption of the mycomembrane led to a shared alteration of the fluidity pattern and susceptibility to two antibiotics, suggesting that membrane fluidity signatures may predict antibiotic susceptibility. This approach expands the toolkit for assessing fluidity in mycobacteria and enables deeper investigation into how biophysical properties influence bacterial physiology and antibiotic susceptibility.
- 7 October 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (11) , 3071-3084
Targeting Mycolic Acid Biosynthesis with Cyclic Sulfamates: A New Strategy against Mycobacterium tuberculosis
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the deadliest infectious disease globally. Current TB regimens involving multidrug cocktails for ≥4 months with significant side effects leave much to be desired, with the first- and second-line drugs inhibiting only a limited number of bacterial targets. Thus, potent antimycobacterial agents with novel targets and mechanisms of action are urgently needed to overcome these limitations and the emergence of multidrug-resistant strains. To address this need, we tested a panel of cyclic sulfamate (CS) compounds and identified novel chemotypes that exhibit potent and highly selective activity against Mtb. Most importantly, multiple lines of evidence that include whole genome sequencing of spontaneous resistant mutants, cell-wall damage reporter assays, modeling of drug-target interactions, and cell wall lipid profiling support the hypothesis that these compounds kill Mtb by inhibiting KasA. KasA encodes a β-ketoacyl synthase, whose role in elongation of acyl-AcpM chains is required for the biosynthesis of mycolic acids. Despite being well validated as an essential enzyme, KasA is still an underexploited drug target in Mtb. In our work, the unchanged susceptibility of CS-resistant mutants to front-line TB drugs provides further evidence that the CS series of compounds acts via a novel mechanism of action. The knowledge gained in this study about structure-activity relationships will guide future medicinal chemistry optimization of the CS scaffold and evaluation of the in vivo efficacy of this chemical series. If successful, this novel chemotype may serve as the starting point for the development of alternative treatment options for TB.
- 7 October 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (11) , 3071-3084
Targeting Mycolic Acid Biosynthesis with Cyclic Sulfamates: A New Strategy against Mycobacterium tuberculosis
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the deadliest infectious disease globally. Current TB regimens involving multidrug cocktails for ≥4 months with significant side effects leave much to be desired, with the first- and second-line drugs inhibiting only a limited number of bacterial targets. Thus, potent antimycobacterial agents with novel targets and mechanisms of action are urgently needed to overcome these limitations and the emergence of multidrug-resistant strains. To address this need, we tested a panel of cyclic sulfamate (CS) compounds and identified novel chemotypes that exhibit potent and highly selective activity against Mtb. Most importantly, multiple lines of evidence that include whole genome sequencing of spontaneous resistant mutants, cell-wall damage reporter assays, modeling of drug-target interactions, and cell wall lipid profiling support the hypothesis that these compounds kill Mtb by inhibiting KasA. KasA encodes a β-ketoacyl synthase, whose role in elongation of acyl-AcpM chains is required for the biosynthesis of mycolic acids. Despite being well validated as an essential enzyme, KasA is still an underexploited drug target in Mtb. In our work, the unchanged susceptibility of CS-resistant mutants to front-line TB drugs provides further evidence that the CS series of compounds acts via a novel mechanism of action. The knowledge gained in this study about structure-activity relationships will guide future medicinal chemistry optimization of the CS scaffold and evaluation of the in vivo efficacy of this chemical series. If successful, this novel chemotype may serve as the starting point for the development of alternative treatment options for TB.
- 12 September 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (10) , 2754-2765
Metabolic Tagging Reveals Surface-Associated Lipoproteins in Mycobacteria
Mycobacteria such as the causative agent of tuberculosis, Mycobacterium tuberculosis (Mtb), encode over 100 bioinformatically predicted lipoproteins. Despite the importance of these post-translationally modified proteins for mycobacterial survival, many remain experimentally unconfirmed. Here we characterized in Mtb and M. smegmatis (Msm) the metabolic incorporation of several modified fatty acids as a facile method of adding chemical groups that enable downstream applications such as detection and enrichment of lipid-modified proteins. We further showed for azido palmitic acid in Msm that incorporation is an active process dependent on the lipoprotein biosynthesis pathway and that a subset of these lipid-modified proteins are associated with the mycobacterial cell surface. Because mycobacteria do not encode known lipoprotein transporters, these data have implications for uncovering the roles of lipoproteins and the possible transport processes involved. Our findings and the tools we validated will enable the further study of pathways related to lipoprotein function in mycobacteria and other bacteria in which lipoproteins remain poorly understood.
- 12 September 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (10) , 2754-2765
Metabolic Tagging Reveals Surface-Associated Lipoproteins in Mycobacteria
Mycobacteria such as the causative agent of tuberculosis, Mycobacterium tuberculosis (Mtb), encode over 100 bioinformatically predicted lipoproteins. Despite the importance of these post-translationally modified proteins for mycobacterial survival, many remain experimentally unconfirmed. Here we characterized in Mtb and M. smegmatis (Msm) the metabolic incorporation of several modified fatty acids as a facile method of adding chemical groups that enable downstream applications such as detection and enrichment of lipid-modified proteins. We further showed for azido palmitic acid in Msm that incorporation is an active process dependent on the lipoprotein biosynthesis pathway and that a subset of these lipid-modified proteins are associated with the mycobacterial cell surface. Because mycobacteria do not encode known lipoprotein transporters, these data have implications for uncovering the roles of lipoproteins and the possible transport processes involved. Our findings and the tools we validated will enable the further study of pathways related to lipoprotein function in mycobacteria and other bacteria in which lipoproteins remain poorly understood.
- Open Access
Measuring membrane fluidity in live mycobacteria reveals subcellular lateral variation and pole-selective responses to mycomembrane perturbation
The cell envelope is an oft-cited factor in the ability of mycobacteria to tolerate antibiotics, host immunity, and environmental stress. In vitro studies have led to a prevailing model in which the mycobacterial envelope exhibits low fluidity that hinders the entry of antibiotics and other stressors. Although fluidity affects essential processes and is dynamically regulated across all domains of life, few studies have measured membrane fluidity in live mycobacteria. To address this gap, we used the environmentally-sensitive probe C-Laurdan to develop an imaging- and flow cytometry-based method for measuring cell envelope fluidity directly in live cells. Our approach enables cell envelope labeling across diverse mycobacterial species, including M. smegmatis and M. tuberculosis . We characterized fluidity as a function of subcellular localization, antibiotic treatment, and genetic perturbation. The unusual growth characteristics of mycobacteria, including polar growth and asymmetric growth and division, contribute to intercellular heterogeneity that is thought to enhance survival under stress. Indeed, we observed that the poles are more fluid than sidewalls, and that the old pole is more fluid than the new pole. Further, daughter cells have unequal membrane fluidity upon division and this asymmetry is reduced in a mutant with decreased asymmetric polar growth. Chemical or genetic disruption of the mycomembrane led to a shared alteration of the fluidity pattern and susceptibility to two antibiotics, suggesting that GP signatures may predict antibiotic susceptibility. This approach expands the toolkit for assessing fluidity in mycobacteria and enables deeper investigation into how biophysical properties influence bacterial physiology and antibiotic susceptibility.
Open AccessMeasuring membrane fluidity in live mycobacteria reveals subcellular lateral variation and pole-selective responses to mycomembrane perturbation
The cell envelope is an oft-cited factor in the ability of mycobacteria to tolerate antibiotics, host immunity, and environmental stress. In vitro studies have led to a prevailing model in which the mycobacterial envelope exhibits low fluidity that hinders the entry of antibiotics and other stressors. Although fluidity affects essential processes and is dynamically regulated across all domains of life, few studies have measured membrane fluidity in live mycobacteria. To address this gap, we used the environmentally-sensitive probe C-Laurdan to develop an imaging- and flow cytometry-based method for measuring cell envelope fluidity directly in live cells. Our approach enables cell envelope labeling across diverse mycobacterial species, including M. smegmatis and M. tuberculosis . We characterized fluidity as a function of subcellular localization, antibiotic treatment, and genetic perturbation. The unusual growth characteristics of mycobacteria, including polar growth and asymmetric growth and division, contribute to intercellular heterogeneity that is thought to enhance survival under stress. Indeed, we observed that the poles are more fluid than sidewalls, and that the old pole is more fluid than the new pole. Further, daughter cells have unequal membrane fluidity upon division and this asymmetry is reduced in a mutant with decreased asymmetric polar growth. Chemical or genetic disruption of the mycomembrane led to a shared alteration of the fluidity pattern and susceptibility to two antibiotics, suggesting that GP signatures may predict antibiotic susceptibility. This approach expands the toolkit for assessing fluidity in mycobacteria and enables deeper investigation into how biophysical properties influence bacterial physiology and antibiotic susceptibility.
- 15 June 2025
- Published by Springer Nature
- Vol. 2921, 139-154
Identifying Inhibitor Targets in Mycobacteria by Activity-Based Probe Profiling
Activity-based protein profiling (ABPP) enables the detection of protein reactivity across entire proteomes. Here, we describe the application of ABPP to the identification of serine hydrolase inhibitor targets in Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis in humans. We highlight the adaptation of stable isotope labeling of amino acids (SILAC) to Mtb using a modified growth medium with an isotopically labeled sole nitrogen source and detail the resulting special requirements for proteomics analysis.
- 15 June 2025
- Published by Springer Nature
- Vol. 2921, 139-154
Identifying Inhibitor Targets in Mycobacteria by Activity-Based Probe Profiling
Activity-based protein profiling (ABPP) enables the detection of protein reactivity across entire proteomes. Here, we describe the application of ABPP to the identification of serine hydrolase inhibitor targets in Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis in humans. We highlight the adaptation of stable isotope labeling of amino acids (SILAC) to Mtb using a modified growth medium with an isotopically labeled sole nitrogen source and detail the resulting special requirements for proteomics analysis.